Neurocrine upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley analyst Jeffrey Hung upgraded Neurocrine to Overweight from Equal Weight with a price target of $130, up from $120. The analyst believes Neurocrine is well positioned for share appreciation with multiple data readouts expected this year. Investors largely expect approval of Ingrezza for Huntington’s disease chorea, but there is incremental upside to the shares with potential approval by the August 20 FDA action date, the analyst tells investors in a research note.